{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T01:14:44Z","timestamp":1774660484196,"version":"3.50.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[1999,10,1]],"date-time":"1999-10-01T00:00:00Z","timestamp":938736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Because chlorofluorocarbons (CFCs) contribute to depletion of stratospheric ozone, CFC-containing metered-dose inhalers (MDIs) such as Ventolin and Proventil are being phased out of production. In terms of delivery of albuterol to the lungs, we compared an alternative delivery system, the Spiros dry-powder inhaler (DPI), with Ventolin, using a methacholine challenge-based clinical bioassay. Twenty-four adults and adolescents with asthma completed this double-blind, four-period crossover study. Doses evaluated were one and three actuations each of Spiros and Ventolin (90- and 270- \u03bc g albuterol base). A methacholine challenge (Cockcroft method) was initiated 3 h before and 0.25 h after albuterol. Predose PC20FEV1 values were not significantly different between study days. Postdose PC20FEV1 results met standard bioassay study validity criteria: i.e., a significant dose\u2013response relationship was present (p = 0.0002); tests for deviation from parallelism and overlap of dose\u2013response curves were nonsignificant (p = 0.08, 0.69). By using Finney 2-by-2 bioassay analysis, we estimate that each Spiros actuation delivers 1.12 times as much albuterol to the airways as one Ventolin actuation (90% confidence interval, 0.68 to 1.94). There were no significant differences in markers of systemic effects (vital signs, potassium, and blood glucose concentrations). We conclude that Spiros and Ventolin inhalers deliver comparable quantities of albuterol to the airways.<\/jats:p>","DOI":"10.1164\/ajrccm.160.4.9806101","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T14:04:20Z","timestamp":1365084260000},"page":"1238-1243","source":"Crossref","is-referenced-by-count":26,"title":["Therapeutic Equivalence of Spiros Dry Powder Inhaler and Ventolin Metered Dose Inhaler: A Bioassay Using Methacholine"],"prefix":"10.1093","volume":"160","author":[{"given":"RICHARD C.","family":"AHRENS","sequence":"first","affiliation":[{"name":"College of Medicine, University of Iowa, Iowa City, Iowa; College of Pharmacy, University of Florida, Gainesville, Florida; International Medical Technical Consultants, Inc., Lenexa, Kansas; and Clinical Development, Dura Pharmaceuticals, Inc., San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LESLIE","family":"HENDELES","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Iowa, Iowa City, Iowa; College of Pharmacy, University of Florida, Gainesville, Florida; International Medical Technical Consultants, Inc., Lenexa, Kansas; and Clinical Development, Dura Pharmaceuticals, Inc., San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WILLIAM R.","family":"CLARKE","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Iowa, Iowa City, Iowa; College of Pharmacy, University of Florida, Gainesville, Florida; International Medical Technical Consultants, Inc., Lenexa, Kansas; and Clinical Development, Dura Pharmaceuticals, Inc., San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ROBERT J.","family":"DOCKHORN","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Iowa, Iowa City, Iowa; College of Pharmacy, University of Florida, Gainesville, Florida; International Medical Technical Consultants, Inc., Lenexa, Kansas; and Clinical Development, Dura Pharmaceuticals, Inc., San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MALCOLM R.","family":"HILL","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Iowa, Iowa City, Iowa; College of Pharmacy, University of Florida, Gainesville, Florida; International Medical Technical Consultants, Inc., Lenexa, Kansas; and Clinical Development, Dura Pharmaceuticals, Inc., San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LEIGH M.","family":"VAUGHAN","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Iowa, Iowa City, Iowa; College of Pharmacy, University of Florida, Gainesville, Florida; International Medical Technical Consultants, Inc., Lenexa, Kansas; and Clinical Development, Dura Pharmaceuticals, Inc., San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHERI","family":"LUX","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Iowa, Iowa City, Iowa; College of Pharmacy, University of Florida, Gainesville, Florida; International Medical Technical Consultants, Inc., Lenexa, Kansas; and Clinical Development, Dura Pharmaceuticals, Inc., San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SEUNG-HO","family":"HAN","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Iowa, Iowa City, Iowa; College of Pharmacy, University of Florida, Gainesville, Florida; International Medical Technical Consultants, Inc., Lenexa, Kansas; and Clinical Development, Dura Pharmaceuticals, Inc., San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[1999,10,1]]},"reference":[{"key":"2026032708483629200_B1"},{"key":"2026032708483629200_B2"},{"key":"2026032708483629200_B3"},{"key":"2026032708483629200_B4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1146\/annurev.pu.14.050193.000555","article-title":"Global change: ozone depletion, greenhouse warming, and public health.","volume":"14","author":"Last","year":"1993","journal-title":"Annu. Rev. Public Health"},{"key":"2026032708483629200_B5"},{"issue":"9","key":"2026032708483629200_B6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1177\/096032719501400903","article-title":"An overview of the toxicology of HFA-134a (1,1,1,2-tetrafluoroethane).","volume":"14","author":"Alexander","year":"1995","journal-title":"Hum. Exp. Toxicol."},{"key":"2026032708483629200_B7"},{"issue":"1","key":"2026032708483629200_B8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0091-6749(95)70032-3","article-title":"Clinical equivalence of a novel non-chlorofluorocarbon-containing salbutamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma.","volume":"96","author":"Dockhorn","year":"1995","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026032708483629200_B9","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1378\/chest.109.3.702","article-title":"Cumulative dose\u2013response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma.","volume":"109","author":"Kleerup","year":"1996","journal-title":"Chest"},{"key":"2026032708483629200_B10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1742-1241.1997.tb11413.x","article-title":"Ease of handling and clinical efficacy of fluticasone propionate Accuhaler\/Diskus inhaler compared with the Turbohaler inhaler in paediatric patients: UK Study Group.","volume":"51","author":"Williams","year":"1997","journal-title":"Br. J. Clin. Pract."},{"key":"2026032708483629200_B11","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/thx.48.11.1186","article-title":"Need for a comparative performance standard for dry powder inhalers.","volume":"48","author":"Richards","year":"1993","journal-title":"Thorax"},{"key":"2026032708483629200_B12","first-page":"258","article-title":"The beta2-agonist controversy: observations, explanations and relationship to asthma epidemiology.","volume":"11","author":"Sears","year":"1994","journal-title":"Drug Safety"},{"key":"2026032708483629200_B13","first-page":"903","article-title":"A method for comparing peak intensity and duration of action of aerosolized bronchodilators using bronchoprovocation with methacholine.","volume":"129","author":"Ahrens","year":"1984","journal-title":"Am. Rev. Respir. Dis."},{"key":"2026032708483629200_B14","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/thx.38.11.854","article-title":"Effect of aerosol fenoterol on the severity of bronchial hyperreactivity in patients with asthma.","volume":"38","author":"Salome","year":"1983","journal-title":"Thorax"},{"key":"2026032708483629200_B15","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/0091-6749(87)90235-1","article-title":"Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in asthmatic patients.","volume":"79","author":"Ahrens","year":"1987","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026032708483629200_B16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1136\/thx.33.6.705","article-title":"Reproducibility and comparison of responses to inhaled histamine and methacholine.","volume":"33","author":"Juniper","year":"1978","journal-title":"Thorax"},{"key":"2026032708483629200_B17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0091-6749(79)90125-8","article-title":"Bronchial responsiveness to inhaled histamine and exercise.","volume":"63","author":"Anderton","year":"1979","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026032708483629200_B18","first-page":"281","article-title":"Asthma induced by cold air and its relationship to nonspecific bronchial responsiveness to methacholine.","volume":"125","author":"O'Bryne","year":"1982","journal-title":"Am. Rev. Respir. Dis."},{"key":"2026032708483629200_B19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2222.1977.tb01448.x","article-title":"Bronchial reactivity to inhaled histamine: a method and clinical survey.","volume":"7","author":"Cockcroft","year":"1977","journal-title":"Clin. Allergy"},{"key":"2026032708483629200_B20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/thx.36.8.575","article-title":"Airway responsiveness to histamine and methacholine: relationship of minimum treatment to control symptoms of asthma.","volume":"36","author":"Juniper","year":"1981","journal-title":"Thorax"},{"key":"2026032708483629200_B21","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJM199210223271703","article-title":"Long-term effects of a long-acting, \u03b22-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma.","volume":"327","author":"Cheung","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"2026032708483629200_B22","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1378\/chest.110.6.1452","article-title":"Tolerance to the protective effect of salmeterol on allergen challenge.","volume":"110","author":"Giannini","year":"1996","journal-title":"Chest"},{"key":"2026032708483629200_B23","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1542\/peds.99.5.655","article-title":"Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise- induced asthma using concurrent inhaled glucocorticoid treatment.","volume":"99","author":"Simons","year":"1997","journal-title":"Pediatrics"},{"key":"2026032708483629200_B24"},{"key":"2026032708483629200_B25","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/BF01068419","article-title":"Pharmacometrics. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.","volume":"15","author":"Schuirmann","year":"1987","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"2026032708483629200_B26","first-page":"149","article-title":"Design and analysis of group sequential tests based on the type I error spending function.","volume":"74","author":"Lan","year":"1983","journal-title":"Biometrika"},{"key":"2026032708483629200_B27","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials.","volume":"35","author":"O'Brien","year":"1979","journal-title":"Biometrics"},{"key":"2026032708483629200_B28"},{"key":"2026032708483629200_B29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0954-6111(95)90085-3","article-title":"Determining equivalence of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at Royal Brompton National Heart & Lung Institute, London, June 24, 1994.","volume":"89","author":"Rogers","year":"1995","journal-title":"Respir. Med."},{"issue":"4","key":"2026032708483629200_B30","first-page":"A66","article-title":"The dose\u2013 response of albuterol MDI during acute attacks of nocturnal asthma (abstract).","volume":"145","author":"Beaty","year":"1992","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2026032708483629200_B31","first-page":"147","article-title":"Relative potencies and rates of decline in effect of inhaled albuterol and terbutaline.","volume":"77","author":"Harris","year":"1986","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026032708483629200_B32"},{"key":"2026032708483629200_B33","first-page":"296","article-title":"On comparing beta adrenergic agonists.","volume":"67","author":"Ahrens","year":"1991","journal-title":"Ann. Allergy"},{"key":"2026032708483629200_B34","first-page":"65s","article-title":"Bioequivalence of CFC salbutamol pressurized MDI and HFA salbutamol pressured MDI on bronchoconstriction to methacholine (abstract).","volume":"12","author":"Parameswaran","year":"1998","journal-title":"Eur. Respir. J."}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/160\/4\/1238\/67427095\/ajrccm_160_4_1238.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/160\/4\/1238\/67427095\/ajrccm_160_4_1238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:49:58Z","timestamp":1774615798000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/160\/4\/1238\/8529488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10,1]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[1999,10,1]]},"published-print":{"date-parts":[[1999,10,1]]}},"URL":"https:\/\/doi.org\/10.1164\/ajrccm.160.4.9806101","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1999,10]]},"published":{"date-parts":[[1999,10,1]]}}}